Gilead Again Pushes To Block Truvada Generic

Law360 (May 21, 2018, 3:06 PM EDT) -- Gilead Sciences Inc. and Emory University accused Aurobindo Pharma Ltd. in Delaware federal court Friday of infringing two of their patents covering the HIV treatment Truvada, the latest in a series of lawsuits attempting to block a generic version of the blockbuster drug.

Aurobindo infringed U.S. Patent Numbers 6,642,245 and 6,703,396 when it filed an abbreviated new drug application with the U.S. Food and Drug Administration hoping to get its generic approved, as both patents are still valid and enforceable, the suit says. The patents expire in 2020 and 2021, according to the FDA's Orange Book.

Gilead received word of the...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!